• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024

    4/16/24 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ABSI alert in real time by email

    VANCOUVER, Wash. and NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the first quarter before market open on Tuesday, May 14, 2024.

    Absci management will webcast a corresponding conference call beginning at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time to discuss its business developments, financial and operating results, and outlook.

    Live audio of the webcast will be available on the company's investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.

    About Absci

    Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Absci's headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.

    Availability of Other Information about Absci

    Investors and others should note that we routinely communicate with investors and the public using our website (www.absci.com) and our investor relations website (investors.absci.com), including without limitation, through the posting of investor presentations, SEC filings, press releases, public conference calls and webcasts on these websites, as well as on X (Twitter), LinkedIn and YouTube. The information that we post on these websites and social media outlets could be deemed to be material information. As a result, investors, the media, and others interested in Absci are encouraged to review this information on a regular basis. The contents of our website and social media postings, or any other website that may be accessed from our website or social media postings, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

    Investor Contact

    Alex Khan

    VP, Finance & Investor Relations

    [email protected]

    Media Contact

    [email protected]



    Primary Logo

    Get the next $ABSI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABSI

    DatePrice TargetRatingAnalyst
    1/22/2025$9.00Buy
    Needham
    10/2/2024$10.00Buy
    Guggenheim
    7/3/2024$7.00Overweight
    Morgan Stanley
    3/14/2024$13.00Sector Outperform
    Scotiabank
    12/5/2023$3.00Overweight
    KeyBanc Capital Markets
    5/4/2023$4.00Buy
    H.C. Wainwright
    8/12/2022Overweight → Underweight
    JP Morgan
    7/18/2022$8.00Buy
    Truist
    More analyst ratings

    $ABSI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Absci to Participate in Upcoming Investor Conferences

      VANCOUVER, Wash. and NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today announced the company will be participating in the following upcoming investor conferences. Jefferies Global Healthcare Conference (New York, NY)Presentation on Thursday, June 5 at 2:00 p.m. Eastern Time / 11:00 a.m. Pacific Time Goldman Sachs 46th Annual Global Healthcare Conference (Miami, FL)Presentation on Monday, June 9 at 8:40 a.m. Eastern Time / 5:40 a.m. Pacific Time TD Cowen 4th Annual Tools/Dx Revolution (Dana Point, CA)June 22-25; Interested parties may contact their TD Cow

      5/20/25 8:00:00 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results

      Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data demonstrate extended half life and high subcutaneous bioavailability; anticipate Phase 1 initiation in early 2026 Cash, cash equivalents, and short-term investments sufficient to fund operations into the first half of 2027 VANCOUVER, Wash. and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative design, today reported financial and operating results for the qu

      5/13/25 4:05:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease

      Absci becomes clinical stage company with ABS-101, first AI-designed biologic for IBD, beginning Phase 1 trial Preclinical data for ABS-101 demonstrates high potency and potential for quarterly dosing, an improvement in efficacy and convenience over first-generation anti-TL1As Interim data anticipated in the second half of 2025 VANCOUVER, Wash., May 13, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI) a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced that the first healthy volunteers have been dosed in a randomized, placebo-controlled Phase 1 study evaluating ABS-101, an investigational anti-TL1A antibody engineer

      5/13/25 4:01:00 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Redmile Group, Llc bought $999,999 worth of shares (222,222 units at $4.50) (SEC Form 4)

      4 - Absci Corp (0001672688) (Issuer)

      3/5/24 9:30:43 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $ABSI
    SEC Filings

    See more
    • Absci Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Absci Corp (0001672688) (Filer)

      6/12/25 4:19:20 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Absci Corporation

      SCHEDULE 13G/A - Absci Corp (0001672688) (Subject)

      5/15/25 7:50:45 PM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Absci Corporation

      SCHEDULE 13G/A - Absci Corp (0001672688) (Subject)

      5/15/25 9:26:58 AM ET
      $ABSI
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care